Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What It’s Really Like To Live With Ulcerative Colitis – A Candid Patient Post

My name is Michaella. I am a 22-year-old lady from Western Massachusetts who got diagnosed with Ulcerative Colitis when I was in 8th grade, nine years ago. When I first started feeling symptoms, I thought I had an allergy to dairy, since dairy seemed to trigger abdominal pain and frequent bathroom visits. Around the holidays…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

My name is Michaella. I am a 22-year-old lady from Western Massachusetts who got diagnosed with Ulcerative Colitis when I was in 8th grade, nine years ago. When I first started feeling symptoms, I thought I had an allergy to dairy, since dairy seemed to trigger abdominal pain and frequent bathroom visits. Around the holidays that year, I told my mom how I was feeling. We went to see my primary care doctor—and I’m glad that we did.

The next day, a Saturday, my primary care physician called to tell my parents I needed to go to the emergency room immediately. My inflammation levels were through the roof.

Introducing a diagnosis—and needle phobia

Starting the minute I walked through the doors of the ER, I was regularly poked with needles to administer fluids and steroids, and conduct blood work. During this time in the hospital, I experienced at least two needle pokes a day. My veins were collapsing due to anemia, which made the situation even worse. All of these pokes caused bruises from my armpits to my wrists by the time my weeklong visit was up. This is when, understandably, my fear of needles began. All the needles required at that time for IV or blood drawing caused nerve damage in my arms.

When I was a sophomore in college, I was prescribed a biologic, which came with an auto injector. I went to my doctor’s office to get the starter dose and learn how to inject myself. They gave me the tester pen and I was good at it. I felt like I could do it myself.

I needed to be administered four starter doses during my first visit. One shot was given to me by my dad in my leg. I did one myself in the other leg, and two nurses gave me one in each arm. It felt like a thousand bee stings. I froze, and the nurses in the room had to remove my shot for me. I began to hysterically cry and hyperventilate. The nurses needed to lay me down and talk to me to calm me. Once I stopped crying, about 20 minutes later, the lead nurse said, “It should not have hurt that bad.”

Well then, I guess my pain tolerance is lower than yours, I thought to myself, raging with anger, and fearing that I would have to regularly go through the whole ordeal again. It was awful.

A new option for self-injections

Ever since then, giving myself self-injections was impossible. I had to be given a sedative to help calm me down, and I had to have my boyfriend, who is also a nurse, administer the medication to me with my mom holding my arms down. It was a tense and stressful process, to say the least. Ultimately, I refused to take the medication, and got a temporary loop ileostomy. I was on the path to a total colectomy, which is the removal of your large intestine and having a permanent ostomy.

I was recently introduced to Portal Instruments. Thanks to the company’s innovative needle-free jet injection platform, I am hopeful that someday I might be able to go back on self-injector medications and reverse my ileostomy. I might be able to live a more normal life thanks to the emphasis on an improved patient experience. A new window of opportunity has been created for me, and I can’t wait to see what the future holds.

Read more at portalinstruments.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512